U.S., May 7 -- ClinicalTrials.gov registry received information related to the study (NCT06959706) titled 'Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors' on April 28.
Brief Summary: The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary anti-tumor activity.
Study Start Date: May 05
Study Type: INTERVENTIONAL
Condition:
Advanced Solid Tumors
Intervention:
DRUG: TGW101
TGW101 is a combination product comprising a chemically cleavable diabody drug conjugate (TGW101-ADC) an...